How important is proper dosing for subcutaneous and sublingual allergy immunotherapy?

2021 ◽  
Vol 42 (5) ◽  
pp. 368-377 ◽  
Author(s):  
Harold S. Nelson

Background: Results of surveys report that allergists use a wide range of doses for allergy immunotherapy; however, results of randomized, double-blind, placebo controlled studies suggest that the range of the optimum effective dosing is relatively narrow. Objective: To review studies that established effective or less than fully effective doses for allergy immunotherapy. Methods: Studies were reviewed that established effective and ineffective subcutaneous and sublingual immunotherapy doses. Only those studies that expressed dosing in terms of the content of a major allergen in the maintenance doses were included in defining effective and ineffective doses. Results: Studies were identified that showed effective doses for subcutaneous injection, established in randomized, double-blind, placebo controlled trials, for short ragweed, timothy grass, house-dust mites, cat and dog dander, birch, and Alternaria. For short ragweed, timothy grass, Dermatophagoides pteronyssinus, and cat and dog dander, less-effective doses were determined, along with effective doses; the less-effective doses were only one-fifth to one-tenth less in allergen content than were the effective doses. Effective doses of cockroach and all fungal extracts except Alternaria have not been established. Information is available on the mean major allergen content of U.S. standardized and a few nonstandardized extracts, which allows the information on effective and ineffective dosing to be used in prescribing subcutaneous allergy immunotherapy. With sublingual allergy immunotherapy, all the approved tablets had multidose studies that determined the optimal dose. For the U.S. liquid extracts, to my knowledge, there are no studies to define effective doses except for ragweed. Conclusions: Although a wide range of doses are prescribed by U.S. allergists, analysis of available data suggests that effective doses fall within a narrow range and that use of doses one-fifth or one-tenth of the effective doses may sacrifice most or all of the potential efficacy of the treatment.

2018 ◽  
Vol 5 (3) ◽  
pp. 373-377
Author(s):  
Shio Priye ◽  
Dipali Singh ◽  
Syed Mudassar ◽  
Shivprakash Shivanna ◽  
Sathyanarayan J

Allergy ◽  
1999 ◽  
Vol 54 (3) ◽  
pp. 249-260 ◽  
Author(s):  
J Bousquet ◽  
P Scheinmann ◽  
MT Guinnepain ◽  
M Perrin‐Fayolle ◽  
J Sauvaget ◽  
...  

2020 ◽  
Author(s):  
Maryam Shamloo ◽  
Matthew J Granger ◽  
Elke A Trautwein ◽  
James D House ◽  
Dylan MacKay

Abstract Background: Functional food ingredients and natural health products have been demonstrated to reduce disease risk and thereby help to lower health care costs across populations at risk for chronic or degenerative diseases. However, typically a wide range of inter-individual variability exists in response across individuals to nutritional and natural health product bioactives, such as plant sterols (PS). This study aims to determine and utilize information on associations between genosets and the degree of responsiveness to dietary PS intervention, with a long-term objective of developing genetic tests to predict response to PS. Methods: This clinical trial is designed as a double blind, placebo controlled, randomized two-period crossover study. 64 eligible participants with the specific a priori -determined single nucleotide polymorphisms (SNPs) associated with responsiveness to PS will consume PS or a placebo treatment for two 4-week periods. The PS treatment consists of two daily single portions of margarine, each providing1 g PS during the PS period (2.0 g/day of PS in total). The placebo will be an identical margarine containing no added PS. LDL-C responsiveness to controlled administration of PS will be investigated as the primary outcome and the associations between inter-individual genoset variabilities and response to PS consumption will be determined. Discussion: This research will provide further insight into whether the associations between previously identified SNPs and the response of LDL-C to PS consumption can be used in a predictive manner. It will also provide insight into the complexities of undertaking a nutrigenetic trial with prospective recruitment based on genotype. Trial registration: The study was registered at ClinicalTrials.gov (Identifier: NCT02765516). Keywords: Plant sterols, Cholesterol, Genetic, SNPs, Prediction


2019 ◽  
Author(s):  
Maryam Shamloo ◽  
Matthew J Granger ◽  
Elke A Trautwein ◽  
James D House ◽  
Dylan MacKay

Abstract Background: Functional food ingredients and natural health products have been demonstrated to reduce disease risk and thereby help to lower health care costs across populations at risk for chronic or degenerative diseases. However, typically a wide range of inter-individual variability exists in response across individuals to nutritional and natural health product bioactives, such as plant sterols (PS). This study aims to determine and utilize information on associations between genosets and the degree of responsiveness to dietary PS intervention, with a long-term objective of developing genetic tests to predict response to PS. Methods: This clinical trial is designed as a double blind, placebo controlled, randomized two-period crossover study. 64 eligible participants with the specific a priori-determined single nucleotide polymorphisms (SNPs) associated with responsiveness to PS will consume PS or a placebo treatment for two 4-week periods. The PS treatment consists of two daily single portions of margarine, each providing1 g PS during the PS period (2.0 g/day of PS in total). The placebo will be an identical margarine containing no added PS. LDL-C responsiveness to controlled administration of PS will be investigated as the primary outcome and the associations between inter-individual genoset variabilities and response to PS consumption will be determined. Discussion: This research will provide further insight into whether the associations between previously identified SNPs and the response of LDL-C to PS consumption can be used in a predictive manner. It will also provide insight into the complexities of undertaking a nutrigenetic trial with prospective recruitment based on genotype. Trial registration: The study was registered at ClinicalTrials.gov (Identifier: NCT02765516). Keywords: Plant sterols, Cholesterol, Genetic, SNPs, Prediction


Sign in / Sign up

Export Citation Format

Share Document